Resultado da Busca
Há 3 dias · Original Article. May 25, 2024. A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection. K.A. Mayer and Others DOI:10.1056/NEJMoa2400763. Correspondence. May 24, 2024. FREE. Cow’s...
Há 2 dias · L.E. Geraghty and OthersN Engl J Med 2024;390:1885-1894. Intubation in neonates is challenging, and repeated attempts are associated with adverse events. Among neonates undergoing urgent ...
Há 2 dias · BACKGROUND: Delayed cerebral ischemia and vasospasm are the most common causes of late morbidity following aneurysmal SAH, but their diagnosis remains challenging. PURPOSE: This systematic review and meta-analysis investigated the diagnostic performance of CTP for detection of delayed cerebral ischemia and vasospasm in the setting of aneurysmal SAH. DATA SOURCES: Studies evaluating the ...
Há 2 dias · Integrating Public Health and Health Care — Protecting Health as a Team Sport. C.A. Wong, D. Houry, and M.K. CohenN Engl J Med 2024;390:1739-1742. Protecting health is a team sport — yet the ...
Há 2 dias · Shelley D. Miyamoto, Daphne T. Hsu and. on behalf of the American Heart Association Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Surgery and Anesthesia; and Council on Cardiovascular and Stroke Nursing. May 29, 2024.
Há 3 dias · TPS2692 Background: Aummune is developing a unique individualized immunotherapy (‘AM003’), designed to have three activities mediated by three different domains: (1) the ‘Variable Domain, identified de novo for each individual patient, based on its ability to specifically induce cell death on patient’s tumor cells; (2) the ‘General Domain’, designed to engage with immune T cells to ...
Há 2 dias · 1.544 - SJR (SCImago Journal Rank) 2023 Speed 9 days submission to first editorial decision for all manuscripts (Median) 86 days submission to accept (Median) 2023 Usage 4,999,990 downloads 8,678 Altmetric mentions
